Skip to content
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — Juli 2022

Genmab — Juli 2022

Planlagt Fastgjort Låst Flyttet Genmab
808 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • P Offline
    P Offline
    ProinvestorNEWS
    wrote on sidst redigeret af
    #683

    Transactions in connection with share buy-back program https://www.proinvestor.com/investornyt/854921/transactions-in-connection-with-share-buy-back-program

    1 Reply Last reply
    0
    • D Offline
      D Offline
      deleted-user
      wrote on sidst redigeret af
      #684

      Fra 72.000 til 18.000 aktier tilbagekøbt på ugebasis. Sommeren er over os 🙂

      1 Reply Last reply
      0
      • L Offline
        L Offline
        lahn1
        wrote on sidst redigeret af
        #685

        Hvem er ham James Bond med butterfly på forsiden ? 😉

        1 Reply Last reply
        0
        • Helge_LarsenPI-redaktørH Offline
          Helge_LarsenPI-redaktørH Offline
          Helge_LarsenPI-redaktør
          wrote on sidst redigeret af
          #686

          Godmorgen. 🙂

          1 Reply Last reply
          0
          • Helge_LarsenPI-redaktørH Offline
            Helge_LarsenPI-redaktørH Offline
            Helge_LarsenPI-redaktør
            wrote on sidst redigeret af
            #687

            lahn...Jeg er klædt på til lejligheden. Det er altid en fest at være på PI. 🙂

            1 Reply Last reply
            0
            • S Offline
              S Offline
              Stroka
              wrote on sidst redigeret af
              #688

              God morgen. 🙂

              1 Reply Last reply
              0
              • P Offline
                P Offline
                ProinvestorNEWS
                wrote on sidst redigeret af
                #689

                Genmab/BMO: Hæver kursmålet med over 100 kr.
                https://www.proinvestor.com/investornyt/855348/genmab-bmo-haever-kursmalet-med-over-100-kr

                1 Reply Last reply
                0
                • J Offline
                  J Offline
                  JKY_VH
                  wrote on sidst redigeret af
                  #690

                  Tak for den og god morgen;-)

                  1 Reply Last reply
                  0
                  • B Offline
                    B Offline
                    bibob
                    wrote on sidst redigeret af
                    #691

                    God morgen. 🙂

                    1 Reply Last reply
                    0
                    • B Offline
                      B Offline
                      bibob
                      wrote on sidst redigeret af
                      #692

                      https://www.onclive.com/view/teclistamab-approaches-eu-approval-for-relapsed-refractory-multiple-myeloma?utm_source=sfmc&utm_medium=email&utm_campaign=07252022_OncLive_SAN-22-OSD1317_MM CC_Sanofi_Sarclisa_GLOBAL&eKey=amFuYm9ydXAxOTc4QGdtYWlsLmNvbQ==
                      Teclistamab.

                      1 Reply Last reply
                      0
                      • D Offline
                        D Offline
                        Doublo
                        wrote on sidst redigeret af
                        #693

                        Godmorgen:-) mon ikke den "generøse" kursforhøjelse fra BMO er et forsøg på at holde kursen nede, sjovt at man kan bruge en kursforhøjelse til det.

                        1 Reply Last reply
                        0
                        • R Offline
                          R Offline
                          Riis7
                          wrote on sidst redigeret af
                          #694

                          Godmorgen, Mon ikke 2500-2600 er fair value på Genmab indtil der kommer nyt for pipeline eller bedre salg på dara 🙂 vi er lige steget fra 1875 til 2600:-) market er stadig meget nervøs med Putins magt over gas/olie . de har os stadig tabt en voldgiftsag på deres bedst sælgende produkt.

                          1 Reply Last reply
                          0
                          • P Offline
                            P Offline
                            peter12
                            wrote on sidst redigeret af
                            #695

                            Ny artikel om HexElect https://www.nature.com/articles/s41587-022-01384-1

                            1 Reply Last reply
                            0
                            • E Offline
                              E Offline
                              E_L
                              wrote on sidst redigeret af
                              #696

                              I wonder if we can deduce from that , that they are actively working on a CD52/CD20 combination

                              1 Reply Last reply
                              0
                              • P Offline
                                P Offline
                                peter12
                                wrote on sidst redigeret af
                                #697

                                They
                                mention CLL several times in the article

                                1 Reply Last reply
                                0
                                • E Offline
                                  E Offline
                                  E_L
                                  wrote on sidst redigeret af
                                  #698

                                  would be nice if we could see some interest in the Hexelect platform with a deal at some point... we are also still waiting for BionTech to say anything about the HexaBody product they are probably working on...

                                  1 Reply Last reply
                                  0
                                  • E Offline
                                    E Offline
                                    E_L
                                    wrote on sidst redigeret af
                                    #699

                                    Btw, another Nature article this month- Changing the face of thyroid eye disease https://www.nature.com/articles/s41433-022-02186-0

                                    1 Reply Last reply
                                    0
                                    • S Offline
                                      S Offline
                                      Sukkeralf
                                      wrote on sidst redigeret af
                                      #700

                                      Just a moment...

                                      favicon

                                      (firstwordpharma.com)

                                      1 Reply Last reply
                                      0
                                      • S Offline
                                        S Offline
                                        Sukkeralf
                                        wrote on sidst redigeret af
                                        #701

                                        Maybe a competitor for Horizon at a later stage in TED

                                        1 Reply Last reply
                                        0
                                        • E Offline
                                          E Offline
                                          E_L
                                          wrote on sidst redigeret af
                                          #702

                                          Janssen Announces New Data Supporting Safety and Efficacy of RYBREVANT® and Lazertinib Combination for Patients with Non-Small Cell Lung Cancer and EGFR Mutations https://www.prnewswire.com/news-releases/janssen-announces-new-data-supporting-safety-and-efficacy-of-rybrevant-and-lazertinib-combination-for-patients-with-non-small-cell-lung-cancer-and-egfr-mutations-301593280.html

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper